{
    "clinical_study": {
        "@rank": "114497", 
        "arm_group": {
            "arm_group_label": "Total Hip Arthroplasty", 
            "description": "Single study group to be implanted with the following combination of components: PROFEMUR\u00ae TL Femoral Stems, DYNASTY\u00ae BioFoam\u00ae Acetabular Components, DYNASTY\u00ae A-Class\u00ae Cross Linked Polyethylene Liners,  and TRASCEND\u00ae/LINEAGE\u00ae Metal Femoral Heads"
        }, 
        "brief_summary": {
            "textblock": "Sponsor is conducting this post market clinical follow-up (PMCF) study to evaluate the\n      safety and efficacy of its total hip arthroplasty (THA) components marketed in the European\n      Union (EU) .  These types of studies are required by regulatory authorities for all THA\n      devices that do not have medium to long-term clinical evidence available at the time of\n      gaining approval to market in the EU.  This study has been designed in accordance with\n      MEDDEV 2.12/2 rev 2."
        }, 
        "brief_title": "Post Market Clinical Follow-up Study Protocol for DYNASTY\u00ae BioFoam\u00ae Acetabular Components", 
        "completion_date": {
            "#text": "July 2028", 
            "@type": "Anticipated"
        }, 
        "condition": "Joint Disease", 
        "condition_browse": {
            "mesh_term": "Joint Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is a candidate for primary unilateral THA for any of the following\n\n          -  Non-inflammatory degenerative joint disease such as osteoarthritis, avascular\n             necrosis, ankylosis, protrusio acetabuli, and painful hip dysplasia\n\n          -  Inflammatory degenerative joint disease such as rheumatoid arthritis\n\n          -  Correction of functional deformity\n\n          -  Subject is able to undergo primary THA procedure\n\n          -  Subject is a candidate to be implanted with the specified combination of components\n\n          -  Subject is willing and able to complete required study visits or assessments\n\n        Exclusion Criteria:\n\n          -  Overt infection\n\n          -  Distant foci of infections (which may cause hematogenous spread to the implant site);\n\n          -  Rapid disease progression as manifested by joint destruction or bone absorption\n             apparent on roentgenogram\n\n          -  Skeletally immature (less than 21 years of age at time of surgery)\n\n          -  Inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate\n             abductor strength), poor bone stock, poor skin coverage around the joint which would\n             make the procedure unjustifiable\n\n          -  Neuropathic joints\n\n          -  Hepatitis or HIV infection\n\n          -  Neurological or musculoskeletal disease that may adversely affect gait or\n             weight-bearing\n\n          -  Subjects currently enrolled in another clinical investigation\n\n          -  Subjects unwilling to sign the Informed Consent document\n\n          -  Subjects with substance abuse issues\n\n          -  Subjects who are incarcerated"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients eligible for total hip arthroplasty"
            }
        }, 
        "enrollment": {
            "#text": "143", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149667", 
            "org_study_id": "12-LJH-002C"
        }, 
        "intervention": {
            "arm_group_label": "Total Hip Arthroplasty", 
            "intervention_name": "total hip arthroplasty implant", 
            "intervention_type": "Device", 
            "other_name": [
                "PROFEMUR\u00ae TL Femoral Stems,", 
                "DYNASTY\u00ae BioFoam\u00ae Acetabular Components,", 
                "DYNASTY\u00ae A-Class\u00ae Cross Linked Polyethylene Liners,", 
                "TRASCEND\u00ae/LINEAGE\u00ae Metal Femoral Heads"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "osteoarthritis", 
            "avascular necrosis", 
            "ankylosis", 
            "protrusio acetabuli", 
            "painful hip dysplasia", 
            "rheumatoid arthritis", 
            "correction of functional deformity", 
            "revision procedures"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ottawa", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "K1H 8L6"
                }, 
                "name": "Ottawa Hospital"
            }, 
            "investigator": {
                "last_name": "Paul Beaule, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "official_title": "Post Market Clinical Follow-up Study Protocol for DYNASTY\u00ae BioFoam\u00ae Acetabular Components", 
        "overall_contact": {
            "email": "lindsey.erwin@ortho.microport.com", 
            "last_name": "Lindsey Erwin, MS", 
            "phone": "(901) 290-5832"
        }, 
        "overall_contact_backup": {
            "email": "leann.speering@ortho.microport.com", 
            "last_name": "Leann Speering, MS", 
            "phone": "(901) 290-5924"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2027", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to estimate component survivorship using Kaplan Meier analysis of all components  out to 10 years follow-up.", 
            "measure": "Component Survivorship", 
            "safety_issue": "No", 
            "time_frame": "10 years post-operative"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149667"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary objective is to characterize total functional scores, as assessed by HOOS Scores and EQ-5D-3L Scores.", 
            "measure": "Patient functional outcomes", 
            "safety_issue": "No", 
            "time_frame": "Pre-operative, 6 months, 1, 3, 5, 7, and 10 years"
        }, 
        "source": "MicroPort Orthopedics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MicroPort Orthopedics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "10 Years", 
        "verification_date": "May 2014"
    }
}